« Return to News | CROs/Service Providers

Covance Profits Down 3% in Q1 as Central Lab Division Suffers Project Delays

Thursday, April 29, 2010 08:09 AM

Covance’s revenues grew and income fell in the first quarter of 2010. The company’s first quarter net revenues were $481.9 million, a 9.2% increase over the same period last year. Net income for the quarter fell 2.9% to $39.1 million, or $0.60 diluted EPS, compared with $40.3 million, or $0.63 diluted EPS, in Q1 2009.

Covance said strong performance from its early- and late-stage clinical development divisions helped offset a weak quarter in central laboratories stemming from slower startup of some new trials.

The company already announced plans to close two underperforming sites this quarter, which will eliminate 200 jobs and result in a cost of approximately $0.09 per share in the second quarter. 

"As a result of these cost actions (and related savings), coupled with the headwinds created by a stronger U.S. dollar, and delays in the commencement of late-stage studies, we are adjusting our 2010 revenue growth rate expectation to the 5%-8% range and our earnings per share target to $2.40 to $2.65,” said Covance chairman and CEO Joe Herring. 

The CRO had originally forecasted 10% revenue growth for 2010 with earnings per share to be in the range of $2.50 to $2.75

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.